195 related articles for article (PubMed ID: 34728570)
1. Targeting DNMTs to Overcome Enzalutamide Resistance in Prostate Cancer.
Farah E; Zhang Z; Utturkar SM; Liu J; Ratliff TL; Liu X
Mol Cancer Ther; 2022 Jan; 21(1):193-205. PubMed ID: 34728570
[TBL] [Abstract][Full Text] [Related]
2. LncRNA PCBP1-AS1-mediated AR/AR-V7 deubiquitination enhances prostate cancer enzalutamide resistance.
Zhang B; Zhang M; Shen C; Liu G; Zhang F; Hou J; Yao W
Cell Death Dis; 2021 Sep; 12(10):856. PubMed ID: 34545063
[TBL] [Abstract][Full Text] [Related]
3. Construction of enzalutamide-resistant cell model of prostate cancer and preliminary screening of potential drug-resistant genes.
Feng T; Wei D; Zhao J; Li Q; Guo P; Yang X; Li M; Jiang Y; Luo Y
Exp Biol Med (Maywood); 2021 Aug; 246(15):1776-1787. PubMed ID: 34034559
[TBL] [Abstract][Full Text] [Related]
4. Copy Number Loss of 17q22 Is Associated with Enzalutamide Resistance and Poor Prognosis in Metastatic Castration-Resistant Prostate Cancer.
Guan X; Sun D; Lu E; Urrutia JA; Reiter RE; Rettig M; Evans CP; Lara P; Gleave M; Beer TM; Thomas GV; Huang J; Aggarwal RR; Quigley DA; Foye A; Chen WS; Youngren J; Weinstein AS; Stuart JM; Feng FY; Small EJ; Xia Z; Alumkal JJ
Clin Cancer Res; 2020 Sep; 26(17):4616-4624. PubMed ID: 32727885
[TBL] [Abstract][Full Text] [Related]
5. Targeting KDM1B-dependent miR-215-AR-AGR2-axis promotes sensitivity to enzalutamide-resistant prostate cancer.
Tang D; He J; Dai Y; Geng X; Leng Q; Jiang H; Sun R; Xu S
Cancer Gene Ther; 2022 May; 29(5):543-557. PubMed ID: 33854217
[TBL] [Abstract][Full Text] [Related]
6. Radiosensitization by enzalutamide for human prostate cancer is mediated through the DNA damage repair pathway.
Sekhar KR; Wang J; Freeman ML; Kirschner AN
PLoS One; 2019; 14(4):e0214670. PubMed ID: 30933998
[TBL] [Abstract][Full Text] [Related]
7. Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance.
McKay RR; Kwak L; Crowdis JP; Sperger JM; Zhao SG; Xie W; Werner L; Lis RT; Zhang Z; Wei XX; Lang JM; Van Allen EM; Bhatt RS; Yu EY; Nelson PS; Bubley GJ; Montgomery RB; Taplin ME
Clin Cancer Res; 2021 Jul; 27(13):3610-3619. PubMed ID: 33849963
[TBL] [Abstract][Full Text] [Related]
8. Antitumor Activity of the IGF-1/IGF-2-Neutralizing Antibody Xentuzumab (BI 836845) in Combination with Enzalutamide in Prostate Cancer Models.
Weyer-Czernilofsky U; Hofmann MH; Friedbichler K; Baumgartinger R; Adam PJ; Solca F; Kraut N; Nguyen HM; Corey E; Liu G; Sprenger CC; Plymate SR; Bogenrieder T
Mol Cancer Ther; 2020 Apr; 19(4):1059-1069. PubMed ID: 32054790
[TBL] [Abstract][Full Text] [Related]
9. Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.
Li J; Hong Z; Zhang J; Zheng S; Wan F; Liu Z; Dai B
Oncogene; 2024 Mar; 43(10):744-757. PubMed ID: 38243079
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological and genetic targeting of 5-lipoxygenase interrupts c-Myc oncogenic signaling and kills enzalutamide-resistant prostate cancer cells via apoptosis.
Monga J; Subramani D; Bharathan A; Ghosh J
Sci Rep; 2020 Apr; 10(1):6649. PubMed ID: 32313135
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer cells survive anti-androgen and mitochondrial metabolic inhibitors by modulating glycolysis and mitochondrial metabolic activities.
Basu HS; Wilganowski N; Robertson S; Reuben JM; Cohen EN; Zurita A; Ramachandran S; Xiao LC; Titus M; Wilding G
Prostate; 2021 Sep; 81(12):799-811. PubMed ID: 34170017
[TBL] [Abstract][Full Text] [Related]
12. Phase I Study of ORIC-101, a Glucocorticoid Receptor Antagonist, in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Progressing on Enzalutamide.
Abida W; Hahn AW; Shore N; Agarwal N; Sieber P; Smith MR; Dorff T; Monk P; Rettig M; Patel R; Page A; Duff M; Xu R; Wang J; Barkund S; Pankov A; Wang A; Junttila MR; Multani PS; Daemen A; Chow Maneval E; Logothetis CJ; Morris MJ
Clin Cancer Res; 2024 Mar; 30(6):1111-1120. PubMed ID: 38226958
[TBL] [Abstract][Full Text] [Related]
13. An androgen receptor-based signature to predict prognosis and identification of ORC1 as a therapeutical target for prostate adenocarcinoma.
Li L; Chen D; Chen X; Zhu J; Bao W; Li C; Miao F; Feng R
PeerJ; 2024; 12():e16850. PubMed ID: 38562999
[TBL] [Abstract][Full Text] [Related]
14. MYC-Mediated Ribosomal Gene Expression Sensitizes Enzalutamide-resistant Prostate Cancer Cells to EP300/CREBBP Inhibitors.
Furlan T; Kirchmair A; Sampson N; Puhr M; Gruber M; Trajanoski Z; Santer FR; Parson W; Handle F; Culig Z
Am J Pathol; 2021 Jun; 191(6):1094-1107. PubMed ID: 33705753
[TBL] [Abstract][Full Text] [Related]
15. A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer.
Palit SAL; van Dorp J; Vis D; Lieftink C; Linder S; Beijersbergen R; Bergman AM; Zwart W; van der Heijden MS
Sci Rep; 2021 Jul; 11(1):13683. PubMed ID: 34211036
[TBL] [Abstract][Full Text] [Related]
16. Tribbles 2 pseudokinase confers enzalutamide resistance in prostate cancer by promoting lineage plasticity.
Monga J; Adrianto I; Rogers C; Gadgeel S; Chitale D; Alumkal JJ; Beltran H; Zoubeidi A; Ghosh J
J Biol Chem; 2022 Feb; 298(2):101556. PubMed ID: 34973338
[TBL] [Abstract][Full Text] [Related]
17. Ferroptosis Inducers Are a Novel Therapeutic Approach for Advanced Prostate Cancer.
Ghoochani A; Hsu EC; Aslan M; Rice MA; Nguyen HM; Brooks JD; Corey E; Paulmurugan R; Stoyanova T
Cancer Res; 2021 Mar; 81(6):1583-1594. PubMed ID: 33483372
[TBL] [Abstract][Full Text] [Related]
18. Non-drug efflux function of ABCC5 promotes enzalutamide resistance in castration-resistant prostate cancer via upregulation of P65/AR-V7.
Chen H; Luo J; Chen S; Shi B; Zheng X; Ji H; Zhang X; Yin Y; Du K; Ding J; Yu Y
Cell Death Discov; 2022 May; 8(1):241. PubMed ID: 35504877
[TBL] [Abstract][Full Text] [Related]
19. A kinome-wide CRISPR screen identifies CK1α as a target to overcome enzalutamide resistance of prostate cancer.
Liu J; Zhao Y; He D; Jones KM; Tang S; Allison DB; Zhang Y; Chen J; Zhang Q; Wang X; Li C; Wang C; Li L; Liu X
Cell Rep Med; 2023 Apr; 4(4):101015. PubMed ID: 37075701
[TBL] [Abstract][Full Text] [Related]
20. Re: Improved Outcomes with Enzalutamide in Biochemically Recurrent Prostate Cancer.
Fernández-Zapata WF; Gandur Quiroga MN; Cardona Maya WD
Eur Urol; 2024 Apr; 85(4):397. PubMed ID: 38087734
[No Abstract] [Full Text] [Related]
[Next] [New Search]
